Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the number of shares and votes in Medivir has changed as a result of redemption of share under the voluntary redemption programme resolved at the extraordinary general meeting on 2 February 2017. The new number of shares has been registered with the Swedish Companies Registration Office during March 2017.
Today, the last trading day of the month, the total number of outstanding shares in Medivir are 20,318,977, whereof 474,769 series A shares and 19,844,208 series B shares, and the total number of votes amounts to 24,597,898 votes.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.
This information is information that Medivir AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on 31 march 2017.
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.